Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
MeiraGTx HoldingsSTU:328 +6.72%61 PB Ratio is 6.39 as of Aug. 20, 2026, which is 104% above its 10-year median of 3.14. GuruFocus rates STU:328 with a GF Score™ of 61/100 and a GF Value™ of €85.22 (Possible Value Trap). The stock has 6 warning signs investors should review. Among 1,214 Biotechnology companies, MeiraGTx Holdings ranks worse than 75.62% on this metric.
The historical rank and industry rank for MeiraGTx Holdings's PB Ratio or its related term are showing as below:
STU:328'
s PB Ratio Range Over the Past 10 Years
Min: 1.82 Med: 3.14 Max: 232.97
Current: 6.54
During the past 10 years, MeiraGTx Holdings's highest PB Ratio was 232.97. The lowest was 1.82. And the median was 3.14.
STU:328's PB Ratio is ranked worse than 75.62% of 1214
companies
in the Biotechnology industry
Industry Median: 2.94
vs STU:328: 6.54
During the past 12 months, MeiraGTx Holdings's average Book Value Per Share Growth Rate was 6086.50% per year.
During the past 10 years, the highest 3-Year average Book Value Per Share Growth Rate of MeiraGTx Holdings was 12.00% per year. The lowest was -40.80% per year. And the median was -24.25% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
MeiraGTx Holdings PB Ratio Related Terms
MeiraGTx Holdings PB Ratio Historical Data
* Premium members only.
The historical data trend for MeiraGTx Holdings's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, MeiraGTx Holdings's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
MeiraGTx Holdings PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, MeiraGTx Holdings's PB Ratio distribution charts can be found below:
* The bar in red indicates where MeiraGTx Holdings's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
MeiraGTx Holdings (STU:328) has a PB Ratio of 6.39 as of Aug. 20, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on MeiraGTx Holdings and its competitors. This is 104% above median its historical median of 3.14. Over the past decade, MeiraGTx Holdings' PB Ratio has ranged from 1.82 to 232.97. According to the industry distribution chart, MeiraGTx Holdings ranks #918 out of 1214 companies in the Biotechnology industry, placing it in the top 75.6%.
Is MeiraGTx Holdings' PB Ratio too high?
MeiraGTx Holdings' current PB Ratio of 6.39 is 104% above median its 10-year median of 3.14. Over the past 10 years, this metric has ranged from a low of 1.82 to a high of 232.97. The Biotechnology industry median PB Ratio is 2.94. MeiraGTx Holdings' value of 6.39 is 117.3% above this industry median. Based on the distribution chart, MeiraGTx Holdings ranks #918 out of 1214 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, MeiraGTx Holdings has a GF Score™ of 61/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does MeiraGTx Holdings' PB Ratio compare to CRVS and WVE?
According to the Biotechnology industry distribution chart, MeiraGTx Holdings ranks #918 out of 1214 companies for PB Ratio. This places MeiraGTx Holdings in the lower half of its industry. The industry median PB Ratio is 2.94. MeiraGTx Holdings' value of 6.39 is 117.3% above this benchmark. Historically, MeiraGTx Holdings' own PB Ratio has ranged from 1.82 to 232.97 over the past decade. While the company's 10-year median is 3.14 vs. the industry median of 2.94, MeiraGTx Holdings has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.94, based on 1,214 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. MeiraGTx Holdings's current PB Ratio of 6.39 is 117.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on MeiraGTx Holdings and its competitors. For the Biotechnology industry, the median PB Ratio is 2.94 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. MeiraGTx Holdings's current PB Ratio is 6.39, which is 104% above median its own 10-year median of 3.14. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MeiraGTx Holdings stock overvalued right now?
Based on GuruFocus' analysis, MeiraGTx Holdings (STU:328) is currently considered Possible Value Trap. The stock's GF Value™ is €85.22, compared to a current price of €12.70 — trading 85.1% below its estimated fair value. The current PB Ratio is 6.39, which is 104% above median its 10-year median of 3.14 and 117.3% above the Biotechnology industry median of 2.94. MeiraGTx Holdings' overall GF Score™ is 61/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For MeiraGTx Holdings (STU:328), the current PB Ratio is 6.39 as of Aug. 20, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is MeiraGTx Holdings (STU:328) Overvalued in 2026?
Based on GuruFocus' analysis, MeiraGTx Holdings stock appears to be undervalued.
The current stock price of €12.70 is trading 85.1% below its estimated GF Value™ of €85.22.
GuruFocus considers MeiraGTx Holdings to be Possible Value Trap.
Key valuation signals for STU:328:
PB Ratio: 6.39 (104% above median its 10-year median of 3.14)
GF Value™: €85.22 vs. price of €12.70 (85.1% below fair value)
Industry Position: 117.3% above the Biotechnology median (#918 of 1214)
No single metric tells the full story. See the STU:328 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
MeiraGTx Holdings PLC is a vertically integrated, clinical-stage genetic medicines company focused on developing targeted therapies for diseases with high unmet need, including radiation-induced xerostomia, Parkinson's disease, and AIPL1-associated retinal dystrophy. The company's pipeline is supported by end-to-end in-house manufacturing capabilities, including GMP viral vector production, plasmid manufacturing, and quality control, enabling development from IND to commercial supply. It also utilizes proprietary platforms in viral vector optimization and riboswitch-based gene regulation to enhance efficacy and reduce dosage. The company operates in the United States, the United Kingdom, and the European Union.
61GF Score
Get the complete analysis for STU:328
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:328 has been successfully added to your 
